Galvan's Week Ahead

Welcome to the Galvan Week ahead report with content supplied exclusively by Galvan. Here we preview the week’s events – both economic and corporate – drawing on the work of the broker’s experienced research and trading teams. It is a mix of fundamental data and technical analysis designed to provide Proactive readers an at a glance guide to what will unfold on the markets over the next five trading days.

For more market moving data visit our Ransquawk column here



Columns found: 198 Show results per page:
  • ASX soars as Medibank's stag catches a snag

    6:08 am

    ASX soars as Medibank's stag catches a snag

    The ASX All Ords soared 1.1% today to 5380, as investors snapped up selected blue chip miners and industrials. Medibank was left in the cold, sinking 1.9% to $2.10.

  • Proteomics seeks $6M for ASX listing to fund protein analysis businesses

    1:50 am

    Proteomics seeks $6M for ASX listing to fund protein analysis businesses

    Proteomics International Laboratories has generated $7.5M in revenues since 2001 and does not intend using its resources to develop diagnostic tools or drugs, but seeks to licence the discovered IP to major pharma groups, who have the required resources for development.

  • Triton Minerals study provides low risk, high returns at Nicanda Hill

    Tue 10:30 pm

    Triton Minerals study provides low risk, high returns at Nicanda Hill

    The scoping study results for Nicanda Hill would see a payback period within less than 12 months and projected strong NPV and IRR results for developing a low cost, high quality graphite mine for arguably the largest known graphite project.

  • Imugene is undervalued v ASX, global peers in Immuno-Oncology

    Tue 9:02 pm

    Imugene is undervalued v ASX, global peers in Immuno-Oncology

    Imugene is an immuno-oncology company developing B-cell based immunotherapies. Immunotherapy has become one of the hottest and most promising areas of study for the treatment of a variety of cancerous tumours. Pfizer and Merck will JV on up to 20 preclinical immuno-oncology programs in 2015.

  • Wall Street ends mixed, oil falls to four-year low

    Tue 9:04 pm

    Wall Street ends mixed, oil falls to four-year low

    U.S. stocks came under pressure Tuesday after a mixed bag of economic reports, including a disappointing consumer confidence report for November.

  • Home Depot to face 44 data breach-related lawsuits in U.S, Canada

    Tue 8:30 pm

    Home Depot to face 44 data breach-related lawsuits in U.S, Canada

    Home Depot (NYSE:HD), the largest U.S. home-improvement retailer, said it faces at least 44 civil lawsuits in the U.S. and Canada related to a widespread data breach earlier this year that affected 56 million debit and credit cards. The company said several state and federal agencies also are looking into the data breach and it may face more litigation from customers, banks, and shareholders.

  • Taseko seen as high cost producer, Dundee Capital downgrades

    Tue 6:48 pm

    Taseko seen as high cost producer, Dundee Capital downgrades

    Taseko Mines (TSE:TKO) was downgraded to a "neutral" rating from "buy" today by analysts at Dundee Capital Markets, who also lowered their price target for the "high cost"  copper producer given the current weak price environment for the metal.

  • TSX rises as U.S. economy expands faster than forecast

    Tue 5:59 pm

    TSX rises as U.S. economy expands faster than forecast

    Canadian shares rose as economic growth in the U.S. expanded more than forecast on consumer spending. The benchmark Standard & Poor’s/TSX Composite Index (TSE:OSPTX) gained 0.4 percent to 15,069.34 at 12:16 p.m. in Toronto. Nine of the 10 industries advanced.